FDA Proposes to Shut the Door on Compounded GLP-1s: What It Means for API and CDMO Suppliers

May 5, 2026 — The U.S. Food and Drug Administration on April 30, 2026 took a decisive step to permanently restrict large-scale compounding of three blockbuster GLP-1 receptor agonists: semaglutide, tirzepatide, and liraglutide. The agency proposed to exclude all three bulk drug substances from the 503B Bulks List, eliminating the last remaining regulatory pathway that allowed outsourcing facilities to mass-produce compounded versions of these drugs.

The proposed rule, published in the Federal Register on May 1, 2026, opens a public comment period through June 30, 2026. FDA Commissioner Marty Makary stated the agency found no clinical need for outsourcing facilities to compound these substances, reinforcing that FDA-approved products are now sufficiently available to meet patient demand.

For API suppliers, CDMOs, and the broader pharmaceutical supply chain, this shift marks a significant inflection point — redirecting billions in demand from compounders back toward legitimate, GMP-compliant API sourcing.

The Regulatory Journey: From Shortage to Surplus

The compounding saga of GLP-1 drugs has been one of the most closely watched regulatory issues in recent years:

• 2022: Semaglutide and tirzepatide placed on FDA's drug shortage list amid surging demand.
• 2023-2024: 503B outsourcing facilities rapidly scaled compounding operations, creating a parallel market estimated at $3-5 billion annually.
• Late 2024 - Early 2025: Tirzepatide (Dec 2024) and semaglutide (Feb 2025) removed from the shortage list as branded manufacturers expanded capacity.
• April 1, 2026: FDA issued guidance confirming neither substance qualifies for compounding under shortage or bulks-list pathways.
• April 30, 2026: FDA proposed permanent exclusion from the 503B Bulks List.

The progression is clear: as branded manufacturers have scaled production, the emergency justification for compounding has evaporated.

Market Impact: Where the Compounded GLP-1 Market Goes

Compounders and Outsourcing Facilities: Approximately 20-30 facilities that ramped up GLP-1 compounding now face a binary choice: pivot to other therapeutic areas or exit. Many invested heavily in peptide synthesis equipment specifically for GLP-1 — investments that now face stranded asset risk.

Branded Manufacturers: Novo Nordisk and Eli Lilly stand to recapture market share previously lost to compounders. Lilly's oral GLP-1 Foundayo (orforglipron), approved in April 2026, adds further supply to the market.

API Supply Chain Shifts

Peptide API Demand Rebalancing:

• The ~50+ compounders sourcing bulk semaglutide and tirzepatide from overseas manufacturers will cease orders, removing substantial unregulated peptide API demand from the market.
• GMP-certified peptide API suppliers serving Novo Nordisk, Lilly, and their CDMO partners will see increased demand as the market consolidates around approved products.
• Bulk peptide prices, inflated by compounding demand, are expected to stabilize as the non-GMP supply channel contracts.

CDMO Opportunities:

• Branded GLP-1 manufacturing: CDMOs with validated peptide synthesis capabilities are positioned for long-term supply agreements as Novo Nordisk and Lilly expand capacity. The peptide CDMO market is projected to grow at 12-15% CAGR through 2030.
• Oral GLP-1 manufacturing: The approval of orforglipron as a small-molecule oral GLP-1 has opened a parallel manufacturing track benefiting conventional small-molecule CDMOs.
• Pivot services: Former compounding facilities transitioning to GMP manufacturing create demand for process development, validation, and regulatory consulting.

Intermediate and Excipient Suppliers:

• Non-GMP peptide synthesis reagent demand (Fmoc amino acids, coupling agents, resins) will decline, while GMP-grade reagent suppliers maintain stable demand.
• Formulation excipient demand may shift as the market moves from compounded formulations to approved pre-filled pen and autoinjector formats.

Strategic Recommendations for B2B Suppliers

• Audit customer base: Identify revenue exposure to compounders and develop transition plans.
• Engage branded manufacturers: Novo Nordisk and Lilly are expanding supplier networks. Early engagement secures long-term positions.
• Invest in peptide GMP capabilities: The long-term trend favors GMP-compliant peptide manufacturing.
• Track oral GLP-1 development: Small-molecule oral GLP-1s shift manufacturing from complex peptide synthesis to conventional processes.
• Prepare for biosimilar competition: As GLP-1 patents approach expiration (2031-2032), biosimilar development will create new API sourcing demand.

Outlook

The FDA's proposed exclusion of GLP-1 drugs from the 503B Bulks List represents the final chapter in a regulatory saga that reshaped the compounding landscape. The long-term effect is a consolidation of GLP-1 supply around FDA-approved, GMP-manufactured products.

For API and CDMO suppliers, the message is clear: the GLP-1 market is entering a phase of maturity characterized by legitimate, regulated supply chains. Companies positioned within these channels are best placed to capture the enormous growth ahead in this $130+ billion therapeutic class.